Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis

Devyani Deshpande, Jotam G. Pasipanodya, Stellah Mpagama, +9

Clinical Infectious Diseases

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis

Devyani Deshpande, Jotam G. Pasipanodya, Stellah Mpagama, +6

Clinical Infectious Diseases

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis

Devyani Deshpande, Shashikant Srivastava, Paula Bendet, +6

Antimicrobial Agents and Chemotherapy

Gatifloxacin Pharmacokinetics/Pharmacodynamics–based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis

Devyani Deshpande, Jotam G. Pasipanodya, Shashikant Srivastava, +10

Clinical Infectious Diseases

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models

Mike Marvin Ruth, Gesham Magombedze, Tawanda Gumbo, +10

Journal of Antimicrobial Chemotherapy

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics

Shashikant Srivastava, Devyani Deshpande, Gesham Magombedze, +9

Journal of Antimicrobial Chemotherapy

Once-a-week tigecycline for the treatment of drug-resistant TB

Devyani Deshpande, Gesham Magombedze, Shashikant Srivastava, +6

Journal of Antimicrobial Chemotherapy